CERE

Cerevel Therapeutics Holdings, Inc. [CERE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CERE Stock Summary

Top 10 Correlated ETFs

CERE


Top 10 Correlated Stocks

CERE


In the News

05:40 26 Feb 2024 CERE

AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

01:35 26 Feb 2024 CERE

AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.

10:50 26 Feb 2024 CERE

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

CNBC's David Faber delivers his latest Faber Report.

10:24 26 Feb 2024 CERE

AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B

AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion.  Cerevel's portfolio includes drugs such as Emraclidine, an experimental treatment for both schizophrenia and Alzheimer's disease psychosis, which is currently in a Phase I study in elderly healthy volunteers.

09:51 26 Feb 2024 CERE

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals to support its growth.

09:45 26 Feb 2024 CERE

Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?

Cerevel Therapeutics (NASDAQ: CERE ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company reached an acquisition deal with AbbVie (NYSE: ABBV ). That deal has AbbVie agreeing to acquire Cerevel Therapeutics for $8.7 billion.

06:46 26 Feb 2024 CERE

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

10:33 26 Feb 2024 CERE

Cerevel options trading surge before AbbVie deal news raises eyebrows

Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer in a multi-billion dollar deal.

06:24 26 Feb 2024 CERE

AbbVie to buy drug developer Cerevel for $8.7 billion

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competition.

05:06 26 Feb 2024 CERE

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.

CERE Financial details

Company Rating
Neutral
Market Cap
7.42B
Income
-392.99M
Revenue
0
Book val./share
1.73
Cash/share
4.3
Dividend
-
Dividend %
-
Employees
321
Optionable
No
Shortable
Yes
Earnings
23 Feb 2024
P/E
-16.93
Forward P/E
-14.19
PEG
-3.17
P/S
-
P/B
24.38
P/C
9.51
P/FCF
-22.72
Quick Ratio
8.59
Current Ratio
8.72
Debt / Equity
1.35
LT Debt / Equity
1.34
-
-
EPS (TTM)
-2.5
EPS next Y
-2.88
EPS next Q
-0.61
EPS this Y
42.33%
EPS next Y
15.09%
EPS next 5Y
15.09%
EPS last 5Y
3.22%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-3.17%
-
-
-
-
SMA20
-0.31%
SMA50
18.07%
SMA100
100.81%
Inst Own
40.68%
Inst Trans
0.46%
ROA
-48%
ROE
-100%
ROC
-0.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
181.43M
Shs Float
86.85M
-
-
-
-
Target Price
52W Range
19.59-43.59
52W High
-4.93%
52W Low
+115.16%
RSI
40.01
Rel Volume
0.34
Avg Volume
3M
Volume
1.02M
Perf Week
-4.69%
Perf Month
-3.65%
Perf Quarter
72.49%
Perf Half Y
78.83%
-
-
-
-
Beta
1.548
-
-
Volatility
0.98%, 0.62%
Prev Close
-0.44%
Price
40.88
Change
-0.29%

CERE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2015-08-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.190000
Net income per share
-1.98-1.01-2.07-1.63-2.32
Operating cash flow per share
-1.63-0.56-1.6-1.31-1.94
Free cash flow per share
-1.66-0.56-1.86-1.38-1.96
Cash per share
0.570.635.214.145.9
Book value per share
0.30.615.224.243.45
Tangible book value per share
-0.390.615.224.243.45
Share holders equity per share
0.30.615.224.243.45
Interest debt per share
0.310.220.450.272.51
Market cap
169.44M1.51B1.22B4.43B4.77B
Enterprise value
165.75M1.46B870.38M4.27B5B
P/E ratio
-6.02-11.78-8.03-19.91-13.57
Price to sales ratio
62.290000
POCF ratio
-7.3-21.39-10.36-24.8-16.27
PFCF ratio
-7.18-21.06-8.93-23.42-16.06
P/B Ratio
40.2219.443.187.659.15
PTB ratio
40.2219.443.187.659.15
EV to sales
60.940000
Enterprise value over EBITDA
-6.03-39.67-5.84-19.41-13.6
EV to operating cash flow
-7.14-20.67-7.39-23.92-17.06
EV to free cash flow
-7.02-20.35-6.37-22.59-16.83
Earnings yield
-0.17-0.08-0.12-0.05-0.07
Free cash flow yield
-0.14-0.05-0.11-0.04-0.06
Debt to equity
1.040.370.090.060.71
Debt to assets
3.250.240.070.050.36
Net debt to EBITDA
0.131.392.350.71-0.63
Current ratio
1.875.8513.2213.5912.48
Interest coverage
-939.23000-38.24
Income quality
0.820.550.770.790.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.860000
Research and developement to revenue
3.560000
Intangibles to total assets
00000
Capex to operating cash flow
0.020.020.160.060.01
Capex to revenue
-0.140000
Capex to depreciation
-0.59-6.21-47.59-3.85-0.81
Stock based compensation to revenue
0.830000
Graham number
3.633.7315.5812.4613.42
ROIC
-3.27-0.62-0.33-0.33-0.4
Return on tangible assets
-20.76-1.06-0.34-0.32-0.35
Graham Net
0.110.294.383.342.62
Working capital
4.54M72.2M361.01M535.48M833.09M
Tangible asset value
-5.55M77.82M384.52M578.73M521.24M
Net current asset value
2.86M44.09M329.81M467.83M409.07M
Invested capital
1.040.370.090.060.71
Average receivables
473.5K00364.5K1.39M
Average payables
4.34M03.55M8.15M10.68M
Average inventory
42K00-364.5K-1.39M
Days sales outstanding
77.430000
Days payables outstanding
305.060000
Days of inventory on hand
00000
Receivables turnover
4.710000
Payables turnover
1.20000
Inventory turnover
00000
ROE
-6.68-1.65-0.4-0.38-0.67
Capex per share
-0.03-0.01-0.26-0.08-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.69-0.59-0.67-0.63-0.61
Operating cash flow per share
-0.53-0.56-0.61-0.49-0.46
Free cash flow per share
-0.53-0.56-0.61-0.51-0.46
Cash per share
6.55.75.284.694.3
Book value per share
3.963.332.762.231.73
Tangible book value per share
3.963.332.762.231.73
Share holders equity per share
3.963.332.762.231.73
Interest debt per share
2.442.42.42.372.36
Market cap
4.3B4.93B3.82B4.99B3.44B
Enterprise value
4.43B5.16B4.03B5.18B3.65B
P/E ratio
-10.27-13.29-9.16-12.54-8.92
Price to sales ratio
00000
POCF ratio
-53.53-56.38-40.25-64.57-47.34
PFCF ratio
-53.42-56.09-40.11-62.89-47.34
P/B Ratio
7.139.468.8514.2412.6
PTB ratio
7.139.468.8514.2412.6
EV to sales
00000
Enterprise value over EBITDA
-49.29-48.13-40.51-53.55-38.98
EV to operating cash flow
-55.04-59.01-42.49-67.03-50.23
EV to free cash flow
-54.92-58.71-42.34-65.29-50.23
Earnings yield
-0.02-0.02-0.03-0.02-0.03
Free cash flow yield
-0.02-0.02-0.02-0.02-0.02
Debt to equity
0.610.710.861.051.35
Debt to assets
0.340.360.40.410.45
Net debt to EBITDA
-1.35-2.15-2.13-1.97-2.24
Current ratio
16.6412.4813.3511.478.72
Interest coverage
-73.92-18.02-15.46-36.68-42.1
Income quality
0.80.940.917.92-9.29
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.0100.030
Capex to revenue
00000
Capex to depreciation
-0.13-0.350.09-1.520
Stock based compensation to revenue
00000
Graham number
7.836.676.435.644.88
ROIC
-0.1-0.12-0.12-0.13-0.17
Return on tangible assets
-0.1-0.09-0.11-0.11-0.12
Graham Net
3.312.532.11.230.81
Working capital
938.64M833.09M777.83M686.11M608.95M
Tangible asset value
603.36M521.24M431.71M350.5M272.96M
Net current asset value
508.31M409.07M342.15M207.82M138.79M
Invested capital
0.610.710.861.051.35
Average receivables
902.5K1.44M2.62M3.67M2.07M
Average payables
12.99M12.52M8.69M8.35M10.47M
Average inventory
7.21M2.77M-2.62M-3.67M-2.07M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.17-0.18-0.24-0.28-0.35
Capex per share
000-0.010

CERE Frequently Asked Questions

What is Cerevel Therapeutics Holdings, Inc. stock symbol ?

Cerevel Therapeutics Holdings, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CERE

Is Cerevel Therapeutics Holdings, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $33.5. The lowest prediction is $27 and the highest is $40

What is CERE stock prediction ?

What is Cerevel Therapeutics Holdings, Inc. stock quote today ?

Cerevel Therapeutics Holdings, Inc. stock price is $40.88 today.

Is Cerevel Therapeutics Holdings, Inc. stock public?

Yes, Cerevel Therapeutics Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks